ALT5 Sigma (ALTS) said Wednesday it plans to separate into two independent public companies, one focused on fintech and the other on biotechnology.
The company said the fintech business will retain the ALT5 name, while the biotech arm will operate as Alyea Therapeutics, creating non-opioid pain management therapies.
The company's board has approved the split, ALT5 added.
ALT5 also said it has named The Ohio Pain Clinic's chairman and founder Amol Soin as the chief executive officer of Alyea Therapeutics.
Shares of ALT5 were up 3.3% in recent early Wednesday trading.
Price: 1.89, Change: +0.06, Percent Change: +3.28
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。